Zenas BioPharma, Inc. Research and Development Expense
Zenas BioPharma, Inc. (ZBIO) reported Research and Development Expense of $62.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Zenas BioPharma, Inc. research and development expense for the quarter ending 2026-06-30 was $62.91M, a 46.22% increase year-over-year.
- Zenas BioPharma, Inc. research and development expense for the quarter ending 2026-03-31 was $60.44M, a 73.10% increase year-over-year.
- Zenas BioPharma, Inc. research and development expense for the quarter ending 2025-12-31 was $55.72M, a 13.35% increase year-over-year.
- Zenas BioPharma, Inc. research and development expense for the quarter ending 2025-09-30 was $34.40M, a 2.60% increase year-over-year.
- Zenas BioPharma, Inc. research and development expense for fiscal 2025 was $168.06M, a 20.79% increase from fiscal 2024.
- Zenas BioPharma, Inc. research and development expense for fiscal 2024 was $139.14M, a 131.77% increase from fiscal 2023.
- Zenas BioPharma, Inc. research and development expense for fiscal 2023 was $60.03M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $62.91M 10-Q · filed 2026-08-13 | $123.35M 10-Q · filed 2026-08-13 | $179.07M derived: sum of 3 quarters · filed 2026-08-13 | $213.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $60.44M 10-Q · filed 2026-05-13 | $116.16M derived: sum of 2 quarters · filed 2026-05-13 | $150.56M derived: sum of 3 quarters · filed 2026-05-13 | $193.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $55.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $90.12M derived: sum of 2 quarters · filed 2026-03-16 | $133.15M derived: sum of 3 quarters · filed 2026-08-13 | $168.06M 10-K · filed 2026-03-16 |
| 2025-09-30 | $34.40M 10-Q · filed 2025-11-12 | $77.43M derived: sum of 2 quarters · filed 2026-08-13 | $112.34M 10-Q · filed 2025-11-12 | $161.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $43.03M 10-Q · filed 2026-08-13 | $77.94M 10-Q · filed 2026-08-13 | $127.10M derived: sum of 3 quarters · filed 2026-08-13 | $160.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $34.91M 10-Q · filed 2026-05-13 | $84.07M derived: sum of 2 quarters · filed 2026-05-13 | $117.60M derived: sum of 3 quarters · filed 2026-05-13 | $151.41M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $49.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $82.69M derived: sum of 2 quarters · filed 2026-03-16 | $116.49M derived: sum of 3 quarters · filed 2026-03-16 | $139.14M 10-K · filed 2026-03-16 |
| 2024-09-30 | $33.53M 10-Q · filed 2025-11-12 | $67.34M derived: sum of 2 quarters · filed 2025-11-12 | $89.98M 10-Q · filed 2025-11-12 | $110.40M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $33.81M 10-Q · filed 2025-08-12 | $56.45M 10-Q · filed 2025-08-12 | $76.87M derived: sum of 3 quarters · filed 2025-08-12 | $86.22M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $22.64M 10-Q · filed 2025-05-15 | $43.06M derived: sum of 2 quarters · filed 2025-05-15 | $52.41M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $20.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $29.77M derived: sum of 2 quarters · filed 2025-03-11 | $60.03M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $9.35M 10-Q · filed 2024-11-12 | $39.62M 10-Q · filed 2024-11-12 |